BioSpace News Archive

The Medicines Company announced the presentation of results from ORION-11, its first pivotal Phase 3 clinical study of inclisiran, an investigational twice-yearly therapy to reduce low-density lipoprotein cholesterol and the first and only cholesterol-lowering therapy in the siRNA class.

Alnylam Pharmaceuticals, Inc. provided perspective on the positive complete results from the ORION-11 Phase 3 study of inclisiran, an RNAi therapeutic in development for the treatment of hypercholesterolemia.

Novaremed AG announced that it has secured CHF2.6 million in additional financing from its existing shareholders and several new private investors.

New NanoWizard 4 XP Provides Extreme Imaging Performance and Ease of Use

The world famous medical journal The Lancet has published the results of a two year health impact trial in Bangladesh

Insilico Medicine has developed GENTRL, a new artificial intelligence system for drug discovery that dramatically accelerates the process from years to days. In the industry’s first successful experimental validation of such AI technology for drug discovery in cells and animals, Insilico successfully tested the technology by creating a series of entirely new molecules capable of combating disorders like fibrosis.

VALBIOTIS (Paris:ALVAL) (FR0013254851 – ALVAL / PEA/SME eligible), a Research & Development company committed to scientific innovation for preventing and combating metabolic diseases, today announced additional positive results from its Phase IIA clinical study2 of VALEDIA

Ardelyx, Inc. announced that it will hold a conference call tomorrow, September 3, at 8:30 am Eastern Time to review the results from the pivotal Phase 3 AMPLIFY study of tenapanor in combination with phosphate binders in patients with chronic kidney disease on dialysis whose hyperphosphatemia was not controlled with binders.

Genentech, a member of the Roche Group, announced that the Phase III MINISTONE-2 study showed that one-dose Xofluza™ was a well-tolerated and effective potential treatment for the flu in otherwise healthy children aged one to less than 12 years old.

Genentech, a member of the Roche Group, announced that the Phase III BLOCKSTONE study showed preventive treatment with Xofluza™ after exposure to an infected household member significantly reduced the risk of people developing the flu by 86 percent versus placebo.